Clinical Trial Update: Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating a dipeptidyl peptidase-4 inhibitor in patients with psoriasis and type 2 diabetes; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Type 2 Diabetes Mellitus

Snippet

Sponsor: University College Dublin | Conditions: Psoriasis, Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2020-05-14